WO2005123746A1 - Methods for preparation of levofloxacin and ofloxacin - Google Patents

Methods for preparation of levofloxacin and ofloxacin Download PDF

Info

Publication number
WO2005123746A1
WO2005123746A1 PCT/CN2004/000954 CN2004000954W WO2005123746A1 WO 2005123746 A1 WO2005123746 A1 WO 2005123746A1 CN 2004000954 W CN2004000954 W CN 2004000954W WO 2005123746 A1 WO2005123746 A1 WO 2005123746A1
Authority
WO
WIPO (PCT)
Prior art keywords
reaction
added
ofloxacin
levofloxacin
solvent
Prior art date
Application number
PCT/CN2004/000954
Other languages
French (fr)
Chinese (zh)
Inventor
Weidong Ye
Weidong Zhang
Zhuhong Yang
Original Assignee
Zhe Jiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhe Jiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory filed Critical Zhe Jiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory
Publication of WO2005123746A1 publication Critical patent/WO2005123746A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems

Definitions

  • the invention belongs to the field of chemistry, and specifically relates to a method for preparing levofloxacin and ofloxacin.
  • Resolution method including high-pressure liquid phase resolution EP206283 (1986) and enzyme resolution (K, Sakano, Agina Biol. Chem .: 1987, 51, 1265) This method is not suitable for industrial production;
  • Levofloxacin UP4777253 (1988) was prepared from tetrafluorobenzoic acid in 7 steps.
  • the synthetic route in this paragraph has the following disadvantages: 1) Due to the different solvents in each step of the reaction (N, N-dimethylformamide or dimethylsulfoxide and water are generally used), the same reaction cannot be performed Continuous operation in the reactor requires four-step operation, large solid transfer volume, dust, and difficult to ensure a satisfactory recovery and application rate of the solvent; 2) In order to meet the two loops at the same time, the reaction is not easy to carry out, making the The temperature is 120 ⁇ 150 ° C and the time is 4 ⁇ 5hr.
  • the reaction time at high temperature is long and side reactions are easy to occur. Product quality and appearance will be affected; 3) A large amount of glacial acetic acid is required, the production cost is large, the hydrolysis reaction time is 5 to 6 hours, the dissolution is difficult, the hydrolysis is not easy to complete, the separation after the reaction is difficult, and the impact on the environment is large.
  • the technical problem to be solved by the present invention is to overcome the shortcomings of the prior art mentioned above, provide a process route for quickly synthesizing levofloxacin and ofloxacin from the compound (V), shorten the reaction time, and simplify the process.
  • the preparation method of levofloxacin is a synthesis method using tetrafluorobenzoic acid as a raw material, which is characterized in that: a) a solvent is added to the crude compound (V), and L is added dropwise by freezing; -Aminopropanol, then incubate until the conversion is complete, add a base, and react at 50-9CTC. After the reaction is complete, add N-methylpiperazine to the mother liquor, stir the reaction at 55 ⁇ 95 ° C for 1-3 hours and reduce the pressure. N-methylpiperazine was recovered, and the reaction temperature was raised to 120-130 ° C, and the temperature was maintained for 0.1 to 1.0 hours. The reaction was ended.
  • the preparation method of ofloxacin is a synthesis method using tetrafluorobenzoic acid as a raw material, which is characterized in that: a) a solvent is added to the crude compound (V), DL-aminopropanol is added dropwise by freezing, and then the temperature is maintained until the conversion is complete Then, add a base and react at 50-90 ° F. After the reaction is completed, add N-methylpiperazine to the mother liquor, stir the reaction at 70-80 ° C for 1-3 hours, and then recover the N-methylpiperazine under reduced pressure. Reaction temperature The temperature was raised to 120_130 ° C, and the temperature was maintained for 0.1 to 1.1 hours. The reaction was terminated.
  • a first ring is firstly placed at a low temperature (60 to 70 ° C), then a methylpiperazinyl group is added, then a second ring is placed at a high temperature (120-13CTC), and finally hydrolyzed.
  • the above-mentioned stepwise ring formation method (which is totally different from the prior art synchronous ring formation method) is adopted, that is, two rings are formed at two different temperatures, the present invention makes the reaction time in the high temperature stage short (0. 1-1 0 hours), most of the reaction time is in the low temperature stage of 60 ⁇ 80 ° C, and the product quality and appearance have been significantly improved.
  • the three reaction processes can be completed in one step in the same reactor, so the compound (V)
  • the preparation of the final product is actually a two-step reaction, which shortens the reaction time.
  • the solvent can be recovered and applied centrally, which reduces the production cost.
  • the hydrolysis is in a fully dissolved state Completed, easier to hydrolyze completely, greatly shortening the reaction time.
  • the solvent is isoamyl alcohol, xylene, dioxane, N, N-dimethylformamide (DMF) or dimethyl sulfoxide ( DMS0), different solvents have an effect on the yield of the reaction.
  • the base in step a is potassium carbonate, sodium bicarbonate, triethylamine or pyridine.
  • the present invention provides a method for preparing levofloxacin and ofloxacin, which has the following beneficial effects: 1) By controlling the reaction temperature, the first ring is added first, then the methylpiperazinyl group is added, and then The second ring is finally hydrolyzed, and the reaction is easy to perform, which shortens the high temperature time and the entire reaction time; 2) The same solvent is used in the reaction process, and the compound (V) can be prepared in the same reactor as the compound (IX) or (X) The inner step is completed, the operation is convenient, the reaction steps are shortened, and the process is simplified; 3) it is convenient to perform centralized recovery of the solvent and apply it, and it has a good recovery and application rate, which reduces the production cost; 4) water The solution is fast and complete; 5) Due to the short high temperature time, the product quality and appearance have been significantly improved.
  • levofloxacin (I) In a 500ml three-necked flask, 50.5g of the compound (IX) obtained in step a, 150ml of water, and 50ml of concentrated hydrochloric acid were sequentially put in and stirred under reflux for half an hour, and the solid was completely dissolved. The reaction is over. After the solution was slightly cold, 150 ml of water and 30. OgNaOH lye were added to adjust the pH to 7.0, and then extracted with 50 ml / times x 5 times of chloroform, and the concentrated chloroform layers were combined to obtain 38.5 g of levofloxacin, Yield: 94.2%.
  • Example 2 3% ⁇ The difference from Example 1 is that using isoamyl alcohol as a solvent, the base added is sodium bicarbonate, the yield obtained in step a is 45.7%, and the yield obtained in step b is 92.3%.
  • Example 3 The difference from Example 3 is that xylene was used as the solvent, the base added was pyridine, the yield obtained in step a was 23.7%, and the yield obtained in step b was 94.6%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The invention relates to the methods for the preparation of anti-infective agents, levofloxacin and ofloxacin. The methods use tetrafluorobenzoic acid as raw material, and are characterized in that a solvent is added to the crude ethyl-2-(2,3,4,5­tetrafluoro-benzoyl)-3-(1-hydroxymethylethamino)acrylate and the freezing L­-aminopropanol or DL-aminopropanol is added dropwise, then maintains the temperature of the reactants to react completely. To the resultant solution is added base and the reaction mixture reacts at 50-90°C while stirring, after the cyclization is finished, N-methylpiperazine is added into the mother solution and reacts for 1-3 h at 55-95 °C, followed by retrieve of N-methylpiperazine under reduced pressure. Then the resulting mixture is heated to 120-130 °C and maintains for 0.1-1.Oh. After suspending the reaction, the reaction solution is poured into water, stirred, cooled, and filtered; to the filtrate are added water and acid, and stirred the reaction mixture at the reflux temperature until hydrolysis completely. Next, the solution is adjusted to pH 7.0 with basic solution and extracted with extracting reagent, then concentrate the extracted layer to give the objective product. The present methods shorten the reaction process, abbreviate the procedure, and facilitates to collect and retrieve solvent and recycle.

Description

左旋氧氟沙星和氧氟沙星的制备方法 技术领域  Preparation method of levofloxacin and ofloxacin Technical field
本发明属于化学领域, 具体地说是一种左旋氧氟沙星和氧氟沙星的制备 方法。  The invention belongs to the field of chemistry, and specifically relates to a method for preparing levofloxacin and ofloxacin.
背景技术 Background technique
氟喹诺酮类药物以其高效、 广谱、 低毒的抗菌特性, 在临床抗感染治疗 方面取得了巨大成功, 日本第一制药公司开发的氧氟沙星及左旋氧氟沙星就 是其中的优秀品种。 左旋氧氟沙星, 英文名: Leovfloxacin , 分子式: C18H20FN304 · 1/2H20, 结构式如下: Fluoroquinolones have achieved great success in clinical anti-infective treatment due to their high-efficiency, broad-spectrum and low-toxic antibacterial properties. Ofloxacin and levofloxacin developed by Daiichi Pharmaceutical Co., Ltd. are among the outstanding varieties . Levofloxacin, English name: Leovfloxacin, molecular formula: C 18 H 20 FN 3 0 4 · 1 / 2H 2 0, the structural formula is as follows:
Figure imgf000002_0001
Figure imgf000002_0001
氧氟沙星, 英文名: Floxacin, 分子式: C18H2。FN304, 结构式如下: Ofloxacin, English name: Floxacin, molecular formula: C 18 H 2 . FN 3 0 4 , the structural formula is as follows:
Figure imgf000002_0002
Figure imgf000002_0002
左氧氟沙星的合成主要有以下三种方法:  There are three main methods for the synthesis of levofloxacin:
1、拆分法:包括高压液相拆分 EP206283( 1986)和酶拆分(K,Sakano, Agina Biol. chem.: 1987, 51 , 1265) 该法不适宜工业化生产;  1. Resolution method: including high-pressure liquid phase resolution EP206283 (1986) and enzyme resolution (K, Sakano, Agina Biol. Chem .: 1987, 51, 1265) This method is not suitable for industrial production;
2、由四氟苯甲酸开始经 7步反应,制备左旋氧氟沙星 UP4777253 ( 1988); 2. Levofloxacin UP4777253 (1988) was prepared from tetrafluorobenzoic acid in 7 steps.
3、 以三氟硝基苯为原料制得。 EP36841 ( 1990)、 EP273399 ( 1988)。 其中方法 2 的成环合成法, 是目前采用的较为普遍的工业化合成方法。 该方法的合成路线如下图所示: 3. Manufactured from trifluoronitrobenzene. EP36841 (1990), EP273399 (1988). Among them, the ring-forming synthesis method of Method 2 is a more common industrialized synthesis method currently used. The synthetic route of this method is shown in the following figure:
Figure imgf000003_0001
Figure imgf000003_0002
Figure imgf000003_0001
Figure imgf000003_0002
Figure imgf000003_0003
Figure imgf000003_0004
Figure imgf000003_0003
Figure imgf000003_0004
( I )  (I)
在上述合成路线中, 当 DL—氨基丙醇与 2- (2, 3, 4, 5-四氟苯甲酰基) - 3-乙氧基 -丙烯酸乙酯(下面简称为化合物 (V) )反应, 采用相似的方法, 就可以制得氧氟沙星, 合成路线如下:
Figure imgf000004_0001
In the above synthetic route, when DL-aminopropanol is reacted with 2- (2, 3, 4, 5-tetrafluorobenzoyl)-3-ethoxy-ethyl acrylate (hereinafter referred to as compound (V)) Ofloxacin can be prepared by a similar method. The synthetic route is as follows:
Figure imgf000004_0001
( II) (III) (IV) (II) (III) (IV)
Figure imgf000004_0002
Figure imgf000004_0002
(XI)  (XI)
在上述的二条合成路线中, 由化合物 (V) 合成最终产物 (左旋氧氟沙 星和氧氟沙星) 的这段路线, 其先同时形成两个环, 然后水解, 最后在 10位 上 N-甲基哌嗪基, 该段合成路线存在以下缺点: 1) 由于反应各步的溶剂不同 (一般采用 N,N—二甲基甲酰胺或二甲基亚砜和水), 无法在同一反应器中连 续操作, 需分四步操作, 固体转移量大, 粉尘多, 且难以保证溶剂得到满意 的回收套用率; 2) 为了满足同时上两个环, 反应不太容易进行, 使制备时的 温度为 120〜150°C, 时间为 4〜5hr, 高温下的反应时间长, 容易发生副反应, 产品质量和外观会受到影响; 3) 需要大量的冰乙酸, 生产成本大, 水解反应 时间长 5〜6hr, 溶解困难, 不容易水解完全, 反应后分离困难, 并且对环境 的影响较大。 In the two synthetic routes described above, the route for the synthesis of the final product (levofloxacin and ofloxacin) from compound (V), which first forms two rings at the same time, then hydrolyzes, and finally N at position 10 -Methylpiperazinyl, the synthetic route in this paragraph has the following disadvantages: 1) Due to the different solvents in each step of the reaction (N, N-dimethylformamide or dimethylsulfoxide and water are generally used), the same reaction cannot be performed Continuous operation in the reactor requires four-step operation, large solid transfer volume, dust, and difficult to ensure a satisfactory recovery and application rate of the solvent; 2) In order to meet the two loops at the same time, the reaction is not easy to carry out, making the The temperature is 120 ~ 150 ° C and the time is 4 ~ 5hr. The reaction time at high temperature is long and side reactions are easy to occur. Product quality and appearance will be affected; 3) A large amount of glacial acetic acid is required, the production cost is large, the hydrolysis reaction time is 5 to 6 hours, the dissolution is difficult, the hydrolysis is not easy to complete, the separation after the reaction is difficult, and the impact on the environment is large.
发明内容 Summary of the invention
本发明所要解决的技术问题是克服上述现有技术的缺陷, 提供一条从化 合物 (V ) 快速合成左氧氟沙星和氧氟沙星的工艺路线, 缩短反应时间, 简 化工艺。  The technical problem to be solved by the present invention is to overcome the shortcomings of the prior art mentioned above, provide a process route for quickly synthesizing levofloxacin and ofloxacin from the compound (V), shorten the reaction time, and simplify the process.
本发明的技术方案是这样的: 左旋氧氟沙星的制备方法, 是以四氟苯甲 酸为原料的合成法, 其特征在于: a)在化合物(V)粗品中加入溶剂, 冷冻滴 加 L-氨基丙醇, 然后保温至转化完全后, 加碱, 在 50-9CTC下反应, 反应完 毕后, 母液中加入 N-甲基哌嗪, 55〜95°C搅拌反应 1-3小时后减压回收 N -甲 基哌嗪, 反应温度升至 120- 130Ό保温 0. 1-1. 0小时, 结束反应, 将反应液倾 入水中, 搅拌, 冷却过滤得 S- (-) 9 -氟- 3-甲基- 10- (4-甲基 -1-哌嗪基) - 7- 氧-- 2, 3-二氢 -7H-吡啶并 -[1, 2, 3, -de] [1, 4]苯并噁嗪- 6-羧酸乙酯(下面 简称为化合物 (IX) ); b)往化合物 (IX ) 中加入水、 酸, 搅拌回流至水解完 全, 用碱液调 ra为 7. 0, 加入萃取剂萃取, 浓缩萃取层即得左旋氧氟沙星。  The technical scheme of the present invention is as follows: The preparation method of levofloxacin is a synthesis method using tetrafluorobenzoic acid as a raw material, which is characterized in that: a) a solvent is added to the crude compound (V), and L is added dropwise by freezing; -Aminopropanol, then incubate until the conversion is complete, add a base, and react at 50-9CTC. After the reaction is complete, add N-methylpiperazine to the mother liquor, stir the reaction at 55 ~ 95 ° C for 1-3 hours and reduce the pressure. N-methylpiperazine was recovered, and the reaction temperature was raised to 120-130 ° C, and the temperature was maintained for 0.1 to 1.0 hours. The reaction was ended. The reaction solution was poured into water, stirred, and cooled to obtain S-(-) 9-fluoro-3. -Methyl- 10- (4-methyl-1-piperazinyl)-7- oxygen-2, 3-dihydro-7H-pyrido- [1, 2, 3, -de] [1, 4 0] benzoxazine-6-carboxylic acid ethyl ester (hereinafter referred to as compound (IX)); b) adding water, acid to compound (IX), stirring and refluxing until the hydrolysis is complete, adjusting the ra to 7.0 with alkaline solution After adding the extractant, the extractive layer was concentrated to obtain levofloxacin.
氧氟沙星的制备方法, 是以四氟苯甲酸为原料的合成法, 其特征在于: a)在化合物(V )粗品中加入溶剂, 冷冻滴加 DL-氨基丙醇, 然后保温至转化 完全后, 加碱, 在 50-90Ό下反应, 反应完毕后, 母液中加入 N-甲基哌嗪, 70-80°C搅拌反应 1-3小时后减压回收 N-甲基哌嗪, 反应温度升至 120_130°C 保温 0. 1-1. 0小时, 结束反应, 将反应液倾入水中, 搅拌, 冷却过滤得 9-氟 _3 -甲基 - 10- (4-甲基- 1-哌嗪基) -7_氧一 2,3-二氢- 7H-吡啶并 - [1, 2, 3, -de] [1, 4]苯并噁嗪- 6-羧酸乙酯 (下面简称为化合物( X ) ) ; b)往化合物( X ) 中加入水、 酸, 搅拌回流至水解完全, 用碱液调 ra为 7. 0, 加入萃取剂萃取, 浓缩萃取层即得氧氟沙星。 - 从化合物 (V ) 制备左旋氧氟沙星的反应历程如下-
Figure imgf000006_0001
The preparation method of ofloxacin is a synthesis method using tetrafluorobenzoic acid as a raw material, which is characterized in that: a) a solvent is added to the crude compound (V), DL-aminopropanol is added dropwise by freezing, and then the temperature is maintained until the conversion is complete Then, add a base and react at 50-90 ° F. After the reaction is completed, add N-methylpiperazine to the mother liquor, stir the reaction at 70-80 ° C for 1-3 hours, and then recover the N-methylpiperazine under reduced pressure. Reaction temperature The temperature was raised to 120_130 ° C, and the temperature was maintained for 0.1 to 1.1 hours. The reaction was terminated. The reaction solution was poured into water, stirred, and cooled and filtered to obtain 9-fluoro_3-methyl-10- (4-methyl-1-piperidine). Azinyl) -7-oxy-2,3-dihydro-7H-pyrido- [1,2,3, -de] [1,4] benzoxazine-6-carboxylic acid ethyl ester (hereinafter referred to as Compound (X)) ; b) Add water and acid to compound (X), stir to reflux until hydrolysis is complete, adjust ra to 7.0 with alkaline solution, add extractant to extract, and concentrate the extract layer to obtain ofloxacin. -The process for preparing levofloxacin from compound (V) is as follows-
Figure imgf000006_0001
(V) (V)
Figure imgf000006_0002
Figure imgf000006_0002
(X) (XI)
Figure imgf000006_0003
(X) (XI)
Figure imgf000006_0003
(IX) ( I ) 实际的反应式如下: (IX) (I) The actual reaction is as follows:
Figure imgf000006_0004
Figure imgf000006_0004
(V) (IX)
Figure imgf000006_0005
(V) (IX)
Figure imgf000006_0005
同理可制得氧氟沙星-
Figure imgf000007_0001
Of course, ofloxacin can be prepared-
Figure imgf000007_0001
( XI)  (XI)
上述的制备方法, 先在低温下 (60〜70°C ) 上第一个环, 接着上甲基哌 嗪基, 然后在高温 (120-13CTC ) 下上第二个环, 最后水解。 由于采用上述的 分步成环法(完全不同于现有技术的同步成环法), 即在两个不同的温度形成 二个环, 本发明使高温阶段的反应时间短 (0. 1-1. 0小时), 大部分反应时间处 于 60〜80°C的低温阶段,产品质量和外观有了明显的改善。由于从化合物(V ) 制备化合物 (D 或 (X ) 的反应过程中使用的是同一种溶剂, 这三个反应 过程可以在同一反应器中一步完成, 所以本发明所涉及的从化合物 (V ) 制 备最终产物实际上是二步反应, 缩短了反应时间, 在反应完毕后可集中回收 溶剂并套用, 降低了生产成本。 此外, 由于先上甲基哌嗪基后水解, 水解在 全溶解状态下完成, 更容易水解完全, 极大地縮短了反应时间。  In the above preparation method, a first ring is firstly placed at a low temperature (60 to 70 ° C), then a methylpiperazinyl group is added, then a second ring is placed at a high temperature (120-13CTC), and finally hydrolyzed. Since the above-mentioned stepwise ring formation method (which is totally different from the prior art synchronous ring formation method) is adopted, that is, two rings are formed at two different temperatures, the present invention makes the reaction time in the high temperature stage short (0. 1-1 0 hours), most of the reaction time is in the low temperature stage of 60 ~ 80 ° C, and the product quality and appearance have been significantly improved. Since the same solvent is used in the reaction for preparing the compound (D or (X)) from the compound (V), the three reaction processes can be completed in one step in the same reactor, so the compound (V) The preparation of the final product is actually a two-step reaction, which shortens the reaction time. After the reaction is completed, the solvent can be recovered and applied centrally, which reduces the production cost. In addition, because the methylpiperazinyl group is firstly hydrolyzed, the hydrolysis is in a fully dissolved state Completed, easier to hydrolyze completely, greatly shortening the reaction time.
所述的左旋氧氟沙星和氧氟沙星的制备方法, 溶剂为异戊醇、 二甲苯、 二氧六环、 N,N—二甲基甲酰胺 (DMF)或二甲基亚砜 (DMS0) , 不同的溶剂对反 应的收率有影响。  In the method for preparing levofloxacin and ofloxacin, the solvent is isoamyl alcohol, xylene, dioxane, N, N-dimethylformamide (DMF) or dimethyl sulfoxide ( DMS0), different solvents have an effect on the yield of the reaction.
所述的左旋氧氟沙星和氧氟沙星的制备方法, a步中的碱为碳酸钾、碳酸 氢钠、 三乙胺或吡啶。  In the method for preparing levofloxacin and ofloxacin, the base in step a is potassium carbonate, sodium bicarbonate, triethylamine or pyridine.
本发明提供了一种左旋氧氟沙星和氧氟沙星的制备方法, 具有以下有益 效果: 1 ) 通过控制反应的温度, 先上第一个环, 接着上甲基哌嗪基, 再上第 二个环, 最后进行水解, 反应容易进行, 縮短了高温时间和整个反应时间; 2) 反应过程中使用同一种溶剂, 化合物 (V ) 制备化合物 (IX) 或 (X ) 可以 在同一反应器内一步完成, 操作方便, 縮短了反应步骤, 简化了工艺; 3)方 便进行集中回收溶剂并套用,且有很好的回收套用率,降低了生产成本; 4)水 解快速且完全; 5) 由于高温时间短, 产品质量和外观有了明显的改善。 The present invention provides a method for preparing levofloxacin and ofloxacin, which has the following beneficial effects: 1) By controlling the reaction temperature, the first ring is added first, then the methylpiperazinyl group is added, and then The second ring is finally hydrolyzed, and the reaction is easy to perform, which shortens the high temperature time and the entire reaction time; 2) The same solvent is used in the reaction process, and the compound (V) can be prepared in the same reactor as the compound (IX) or (X) The inner step is completed, the operation is convenient, the reaction steps are shortened, and the process is simplified; 3) it is convenient to perform centralized recovery of the solvent and apply it, and it has a good recovery and application rate, which reduces the production cost; 4) water The solution is fast and complete; 5) Due to the short high temperature time, the product quality and appearance have been significantly improved.
具体实施方式 detailed description
实施例 1  Example 1
a)化合物 (IX) 的制备: 在 500ml的三颈瓶中投入 60. Og化合物 (V )、 150ml DMF, 冷冻至 0°C, 滴加 14. Og L-氨基丙醇, 然后保温 0. 5小时后, 加 入 45. 0gK2CO3, 60-70°C反应 3小时, 母液中加入 30. Og N-甲基哌嗪, 70-80 °C搅拌反应 2小时后减压回收 N-甲基哌嗪。 升高反应温度至 120- 130°C, 0. 5 小时后, 反应结束, 反应液倾入装有 500ml水的 1000ml烧杯中, 搅拌, 即有 白色固体析出, 冷却过滤、 干燥得 43. Og化合物 (IX ), 收率 57. 9%。  a) Preparation of compound (IX): Put 60. Og of compound (V), 150 ml of DMF in a 500-ml three-necked flask, freeze to 0 ° C, dropwise add 14. Og L-aminopropanol, and then incubate at 0.5 After 4 hours, 45.0 g of K2CO3 was added, and the mixture was reacted at 60-70 ° C for 3 hours. 30. Og of N-methylpiperazine was added to the mother liquor, and the reaction was stirred at 70-80 ° C for 2 hours to recover N-methylpiperazine under reduced pressure. Og Compound Raise the reaction temperature to 120-130 ° C, 0.5 hours later, the reaction is completed, the reaction solution is poured into a 1000ml beaker containing 500ml of water, and stirred, that is, a white solid precipitates, cooled, filtered, and dried to obtain 43. Og compounds (IX), with a yield of 57.9%.
b)左旋氧氟沙星 ( I ) 的制备: 在 500ml的三颈瓶中依次投入 a步中得 到的 50. 5g化合物 (IX)、 150ml水、 50ml浓盐酸, 搅拌回流半小时, 固体完 全溶解, 反应结束。 溶液稍冷后加入 150ml水与 30. OgNaOH配制的碱液调 PH 为 7. 0, 然后用 50ml/次 X 5次的氯仿萃取, 合并浓缩氯仿层, 得 38. 5 g左旋 氧氟沙星, 收率 94. 2%。  b) Preparation of levofloxacin (I): In a 500ml three-necked flask, 50.5g of the compound (IX) obtained in step a, 150ml of water, and 50ml of concentrated hydrochloric acid were sequentially put in and stirred under reflux for half an hour, and the solid was completely dissolved. The reaction is over. After the solution was slightly cold, 150 ml of water and 30. OgNaOH lye were added to adjust the pH to 7.0, and then extracted with 50 ml / times x 5 times of chloroform, and the concentrated chloroform layers were combined to obtain 38.5 g of levofloxacin, Yield: 94.2%.
实施例 2  Example 2
与实施例 1 的不同之处在于, 采用异戊醇作为溶剂, 加入的碱为碳酸氢 钠, a步得到的收率为 45. 7 %, b步得到的收率为 92. 3%。  3%。 The difference from Example 1 is that using isoamyl alcohol as a solvent, the base added is sodium bicarbonate, the yield obtained in step a is 45.7%, and the yield obtained in step b is 92.3%.
实施例 3  Example 3
a)化合物( X )的制备:在 500ml的三颈瓶中依次投入 60. 0g化合物( V )、 150mlDMF, 冷冻至 0°C, 滴加 14. 0g DL-氨基丙醇, 然后保温 0. 5小时后, 加 Λ 45. 0gK2CO3, 60 - 70°C反应 3小时, 母液中加入 30. 0g N-甲基哌嗪, 70-80 °C搅拌反应 2小时后减压回收 N-甲基哌嗪。 升高反应温度至 120-130°C, 0. 5 小时后, 反应结束, 反应液倾入装有 500ml水的 1000ml烧杯中, 搅拌, 即有 白色固体析出, 冷却过滤、 干燥得 45. 0g, 收率 60. 6%。  a) Preparation of compound (X): In a 500ml three-necked flask, 60.0g of compound (V), 150ml of DMF were sequentially put in, frozen to 0 ° C, 14.0g of DL-aminopropanol was added dropwise, and then kept at 0.5 After 4 hours, add Λ 45.0 gK2CO3, react at 60-70 ° C for 3 hours, add 30.0 g of N-methylpiperazine to the mother liquor, and stir at 70-80 ° C for 2 hours to recover N-methylpiperazine under reduced pressure. . 0g , Raising the reaction temperature to 120-130 ° C, 0.5 hours later, the reaction was completed, the reaction solution was poured into a 1000ml beaker filled with 500ml of water, and stirred, that is, a white solid precipitated, cooled and dried to 45.0g, Yield: 60.6%.
b)氧氟沙星 (XI) 的制备: 在 500ml的三颈瓶中依次投入 a步中得到的 b) Preparation of ofloxacin (XI): Put the obtained in step a in a 500ml three-necked bottle in turn.
52. 0g固体化合物、 150ml水、 50ml浓盐酸, 搅拌回流半小时, 反应结束。 溶 液稍冷后加入 400ml 乙醇, 即析出大量白色固体, 搅拌冷冻后过滤、 干燥得 41. 5g氧氟沙星, 收率 97. 1%。 52.0 g of a solid compound, 150 ml of water, and 50 ml of concentrated hydrochloric acid were stirred under reflux for half an hour, and the reaction was completed. After the solution was slightly cold, 400 ml of ethanol was added to precipitate a large amount of white solid. After stirring and freezing, it was filtered and dried to obtain 41.5 g of ofloxacin with a yield of 97.1%.
实施例 4  Example 4
与实施例 3的不同之处在于, 采用二甲苯作为溶剂, 加入的碱为吡啶, a 步得到的收率为 23. 7 %, b步得到的收率为 94. 6%。  The difference from Example 3 is that xylene was used as the solvent, the base added was pyridine, the yield obtained in step a was 23.7%, and the yield obtained in step b was 94.6%.

Claims

权 利 要 求 Rights request
1、 左旋氧氟沙星的制备方法, 是以四氟苯甲酸为原料的合成法, 其特征 在于: a)在 2- ( 2, 3, 4, 5-四氟苯甲酰基) -3-乙氧基-丙烯酸乙酯粗品中加 入溶剂, 冷冻滴加 L-氨基丙醇, 然后保温至转化完全后, 加碱, 在 50-9CTC 下反应, 反应完毕后, 母液中加入 N-甲基哌嗪, 55〜95°C搅拌反应 1-3小时 后减压回收 N-甲基哌嗪, 反应温度升至 120-130°C保温 0. 1-1. 0小时, 结束 反应, 将反应液倾入水中, 搅拌, 冷却过滤得 S- (-) 9-氟 -3-甲基 -10- ( 4- 甲基- 1-哌嗪基) - 7_氧-- 2,3-二氢 -7H-吡啶并 - [1, 2, 3, - de] [l,4]苯并噁 嗪 -6-羧酸乙酯; b)往 a步所得的产物中加入水、 酸, 搅拌回流至水解完全, 用碱液调 ra为 7. 0, 加入氯仿萃取, 浓缩萃取层即得左旋氧氟沙星。 1. The preparation method of levofloxacin is a synthesis method using tetrafluorobenzoic acid as a raw material, which is characterized by: a) in 2- (2, 3, 4, 5-tetrafluorobenzoyl) -3- A solvent was added to the crude ethoxy-ethyl acrylate, and L-aminopropanol was added dropwise by freezing. After the temperature was kept constant, the base was added and reacted at 50-9CTC. After the reaction was completed, N-methyl piperazine was added to the mother liquor. Azine, 55 ~ 95 ° C, stirred for 1-3 hours to recover N-methylpiperazine under reduced pressure, and the reaction temperature was raised to 120-130 ° C, and the temperature was maintained for 0.1 to 1.1 hours, the reaction was terminated, and the reaction solution was poured. Pour into water, stir, cool and filter to obtain S- (-) 9-fluoro-3-methyl-10- (4-methyl-1-piperazinyl)-7_oxy-2,3-dihydro-7H -Pyrido- [1,2,3, -de] [l, 4] benzoxazine-6-carboxylic acid ethyl ester; b) water and acid are added to the product obtained in step a, and the mixture is stirred and refluxed until the hydrolysis is completed , Ra was adjusted to 7.0 with alkaline solution, chloroform extraction was added, and the extracted layer was concentrated to obtain levofloxacin.
2、 根据权利要求 1所述的左旋氧氟沙星的制备方法, 其特征在于所述的 溶剂为异戊醇、 二甲苯、 二氧六环、 N,N—二甲基甲酰胺或二甲基亚砜。  2. The method for preparing levofloxacin according to claim 1, wherein the solvent is isoamyl alcohol, xylene, dioxane, N, N-dimethylformamide or dimethyl Sulfoxide.
3、 根据权利要求 1所述的左旋氧氟沙星的制备方法, 其特征在于 a步中 的碱为碳酸钾、 碳酸氢钠、 三乙胺或吡啶。  3. The method for preparing levofloxacin according to claim 1, wherein the base in step a is potassium carbonate, sodium bicarbonate, triethylamine or pyridine.
4、氧氟沙星的制备方法, 是以四氟苯甲酸为原料的合成法,其特征在于: a)在 2- (2, 3, 4, 5-四氟苯甲酰基)-3-乙氧基-丙烯酸乙酯粗品中加入溶剂, 冷冻滴加 DL-氨基丙醇, 然后保温至转化完全后, 加碱, 在 50-90Ό下反应, 反应完毕后, 母液中加入 N-甲基哌嗪, 55〜95°C搅拌反应 1-3小时后减压回 收 N-甲基哌嗪, 反应温度升至 120-130°C保温 0. 1-1. 0小时, 结束反应, 将 反应液倾入水中, 搅拌, 冷却过滤得 9-氟- 3-甲基 -10- (4-甲基 -1-哌嗪基) - 7 -氧一 2, 3-二氢- 7H-吡啶并 - [1, 2 , 3, _de] [1, 4]苯并噁嗪- 6-羧酸乙酯; b)往 a步所得的产物中加入水、酸,搅拌回流至水解完全,用碱液调 PH为 7. 0, 加入氯仿萃取, 浓缩萃取层即得氧氟沙星。  4. The preparation method of ofloxacin is a synthesis method using tetrafluorobenzoic acid as a raw material, which is characterized by: a) at 2- (2, 3, 4, 5-tetrafluorobenzoyl) -3-ethyl A solvent was added to the crude oxy-ethyl acrylate, and DL-aminopropanol was added dropwise by freezing. After the temperature was kept constant, the base was added and reacted at 50-90 ° F. After the reaction was completed, N-methylpiperazine was added to the mother liquor. , 55 ~ 95 ° C, stirring the reaction for 1-3 hours, and then recovering N-methylpiperazine under reduced pressure, the reaction temperature was raised to 120-130 ° C, and the temperature was maintained for 0. 1-1. 0 hours, the reaction was terminated, and the reaction solution was poured into Stir in water and filter with cooling to obtain 9-fluoro-3-methyl-10- (4-methyl-1-piperazinyl) -7-oxo-2,3-dihydro-7H-pyrido- [1, 2, 3, _de] [1,4] benzoxazine-6-carboxylic acid ethyl ester; b) add water and acid to the product obtained in step a, stir and reflux until the hydrolysis is complete, adjust the pH to 7 with alkaline solution 0, add chloroform for extraction, and concentrate the extraction layer to obtain ofloxacin.
5、 根据权利要求 4所述的氧氟沙星的制备方法, 其特征在于所述的溶剂 为异戊醇、 二甲苯、 二氧六环、 N,N—二甲基甲酰胺或二甲基亚砜。  5. The method for preparing ofloxacin according to claim 4, characterized in that the solvent is isoamyl alcohol, xylene, dioxane, N, N-dimethylformamide or dimethyl Sulfoxide.
6、 根据权利要求 4所述的氧氟沙星的制备方法, 其特征在于 a步中的碱 为碳酸钾、 碳酸氢钠、 三乙胺或吡啶。  6. The method for preparing ofloxacin according to claim 4, wherein the base in step a is potassium carbonate, sodium bicarbonate, triethylamine or pyridine.
PCT/CN2004/000954 2004-06-22 2004-08-16 Methods for preparation of levofloxacin and ofloxacin WO2005123746A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB200410155139XA CN100412075C (en) 2004-06-22 2004-06-22 Process for preparing L-ofloxacin and ofloxacin
CN200410155139.X 2004-06-22

Publications (1)

Publication Number Publication Date
WO2005123746A1 true WO2005123746A1 (en) 2005-12-29

Family

ID=34667283

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2004/000954 WO2005123746A1 (en) 2004-06-22 2004-08-16 Methods for preparation of levofloxacin and ofloxacin

Country Status (2)

Country Link
CN (1) CN100412075C (en)
WO (1) WO2005123746A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101514208B (en) * 2008-10-17 2011-03-16 浙江京新药业股份有限公司 Green synthesizing process for ofloxacin
CN114507242A (en) * 2022-01-26 2022-05-17 上虞京新药业有限公司 Preparation method of high-optical-purity levofloxacin

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101648960B (en) * 2009-09-04 2011-08-10 诚达药业股份有限公司 Method for preparing ofloxacin
CN103113388B (en) * 2013-02-01 2016-02-10 浙江国邦药业有限公司 A kind of preparation method of levofloxacin
CN105198904B (en) * 2014-06-25 2017-08-15 上虞京新药业有限公司 The preparation method of lavo-ofloxacin and Ofloxacin
CN107677735A (en) * 2016-08-02 2018-02-09 上海朴颐化学科技有限公司 A kind of HPLC analysis methods of (S) 2 aminopropanol
CN112552261A (en) * 2019-09-26 2021-03-26 宜昌东阳光长江药业股份有限公司 Preparation method of levofloxacin and intermediate thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62215591A (en) * 1986-03-14 1987-09-22 Dainippon Pharmaceut Co Ltd Production of pyridobenzoxazine derivative and intermediate therefor
US4777253A (en) * 1986-04-25 1988-10-11 Abbott Laboratories Process for preparation of racemate and optically active ofloxacin and related derivatives
US5639886A (en) * 1993-12-10 1997-06-17 Bayer Aktiengesellschaft One-pot process for the preparation of 3-quinolonecarboxylic acid derivatives
JP2001031654A (en) * 1999-07-22 2001-02-06 Fuji Yakuhin:Kk New quinolinecarboxylic acid derivative and its production and use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746986A (en) * 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
ES2272781T5 (en) * 2001-10-03 2010-04-06 Teva Pharmaceutical Industries Ltd. PREPARATION OF HEMIHYDRATED LEVOFLOXACINO.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62215591A (en) * 1986-03-14 1987-09-22 Dainippon Pharmaceut Co Ltd Production of pyridobenzoxazine derivative and intermediate therefor
US4777253A (en) * 1986-04-25 1988-10-11 Abbott Laboratories Process for preparation of racemate and optically active ofloxacin and related derivatives
US5639886A (en) * 1993-12-10 1997-06-17 Bayer Aktiengesellschaft One-pot process for the preparation of 3-quinolonecarboxylic acid derivatives
JP2001031654A (en) * 1999-07-22 2001-02-06 Fuji Yakuhin:Kk New quinolinecarboxylic acid derivative and its production and use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
QI J. ET AL: "SYNTHESIS OF OFLOXACIN AND ITS OPTICAL ISOMERS", CHINESE JOURNAL OF PHARMACEUTICALS, vol. 29, no. 6, 1998, pages 243 - 245 *
YANG Y. ET AL: "A NEW PRACTICAL ROUTE TO STEREOSPECIFIC SYNTHESIS OF (S)-(-)-OFLOXACIN", ACTA PHARMACEUTICAL SINICA, vol. 33, no. 11, 1998, pages 828 - 831 *
YANG Y. ET AL: "STUDIES ON SYNTHESIS ANTIBACTERIAL AND ANTITUMOR ACTIVITY OF (S)-(-)-OFLOXACIN ANALOGUES", ACTA PHARMACEUTICA SINICA, vol. 34, no. 2, 1999, pages 119 - 124 *
YANG Y. ET AL: "SYNTHESIS AND STRUCTURE ACTIVITIES RELATIONSHIP OF LEVOFLOXACIN ANALOGUES", ACTA PHARMACEUTICA SINICA, vol. 34, no. 2, 1999, pages 197 - 202 *
YANG Y.-S. ET AL: "A practical stereoselective synthesis of (S)-(-)-ofloxacin", CHINESE JOURNAL OF CHEMISTRY, vol. 17, no. 5, 1999, pages 539 - 544 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101514208B (en) * 2008-10-17 2011-03-16 浙江京新药业股份有限公司 Green synthesizing process for ofloxacin
CN114507242A (en) * 2022-01-26 2022-05-17 上虞京新药业有限公司 Preparation method of high-optical-purity levofloxacin

Also Published As

Publication number Publication date
CN100412075C (en) 2008-08-20
CN1594320A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
US20110160458A1 (en) Process and intermediates for preparing integrase inhibitors
US8962832B2 (en) Process for the preparation of ambrisentan and novel intermediates thereof
WO2008087557A2 (en) An improved process for preparation of 9-hydroxy-3-(2-chloroethyl)- 2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one hydrochloride
KR101275092B1 (en) Manufacturing Method Of Azilsartan
WO2005123746A1 (en) Methods for preparation of levofloxacin and ofloxacin
CN101648960A (en) Method for preparing ofloxacin
US8735585B2 (en) Indenopyridine derivatives
JP3930736B2 (en) Method for producing pyridinemethanol compound
KR101316653B1 (en) Manufacturing Method Of Hetero Cyclic Compound
KR100990046B1 (en) New 4-halobenzylamine salts of montelukast and process for preparing montelukast sodium by using them
WO2018059427A1 (en) Method for preparing phenylalanine compound
JP2015038053A (en) Method for producing 4-(2-methyl-1-imidazolyl)-2,2-phenylbutane amide
WO2020147803A1 (en) SYNTHESIS OF 3-BROMO-5-(2-ETHYLIMIDAZO[1,2-α]PYRIDINE-3-CARBONYL)-2-HYDROXYBENZONITRILE
RU2228929C2 (en) Method for preparing (3s)-3-amino-3-pyridylpropionic acid and intermediate substance
US8198455B2 (en) Process for the preparation of dexlansoprazole
EP3356372B1 (en) Novel process for preparing thienopyrimidine compound and intermediates used therein
US20130109865A1 (en) Methods of preparing 1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone
US20120123127A1 (en) Process for producing thiabenzoazulene-propionic acid derivative
JP2003201281A (en) Method for producing 4-(2-methyl-1-imidazolyl)-2,2- diphenylbutane amide
CN110563648B (en) Method for preparing blonanserin intermediate (BN-04)
EP1539751B1 (en) Process for the preparation of imidazo(1,2-a)pyridine-3-acetamides
JP5087059B2 (en) Process for producing 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutanamide
CN114751850A (en) Preparation method of key intermediate of BTK kinase inhibitor
CN117510400A (en) Preparation method of 6-bromo-2-chloro-3-nitropyridine
CN117624009A (en) Continuous synthesis method of JAK inhibitor drug heterocyclic intermediate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase